1349 On Other Exchanges
Symbol
Exchange
1349 is not on other exchanges.

shanghai fudan-zhangjiang-h (1349) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FUDAN-ZHANGJIANG-H (1349)

Related News

No related news articles were found.

shanghai fudan-zhangjiang-h (1349) Related Businessweek News

No Related Businessweek News Found

shanghai fudan-zhangjiang-h (1349) Details

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic technical platform drugs, including recombinant human lymphotoxin a-derivatives that has completed Phase II clinical trials for tumors; recombinant human TNF receptor 2-Fc fusion protein mutant, which is in Phase I clinical trials for the treatment of arthritis; PTH that has completed Phase I clinical trials for osteoporosis; CD30-MMAE, which is in pre-clinical studies for tumors; Anti-sclerostin mab that is in pre-clinical studies for osteoporosis; and Avastin, which has completed pre-clinical study for tumors. The company also provides photodynamic technical platform drugs, such as Hemoporfin for port wine stain; Deuteroporphyrin that is in Phase II clinical trials for tumors; Aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV; and Aminolevulinic acid that has submitted application for clinical trials for acne, as well as is in pre-clinical studies for brain gliomas and basal cell carcinoma. In addition, it offers Nano technical platform drugs comprising Vincristine sulphate liposome, which has completed Phase I clinical trials for tumors; and Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company is developing food safety inspection reagents for antibiotics inspection, etc., as well as researches and develops biological and medical technology, pharmaceutical projects, and medical diagnostic products. Additionally, it engages in the provision of medical investment management, health industry management, projects investment, assets management, investment and business consultation, and medical and enterprise management consultation activities. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

605 Employees
Last Reported Date: 03/29/17
Founded in 1996

shanghai fudan-zhangjiang-h (1349) Top Compensated Officers

Co-Founder, Executive Chairman and General Ma...
Total Annual Compensation: CNY1.9M
Co-Founder, Deputy General Manager and Execut...
Total Annual Compensation: CNY1.2M
Deputy General Manager and Executive Director
Total Annual Compensation: CNY1.2M
Compensation as of Fiscal Year 2016.
shanghai fudan-zhangjiang-h
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2016, Payable on 21 August 2017

The Board of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has recommended a final dividend of RMB 0.05 per share (tax inclusive) for the year ended 31 December 2016, totaling approximately RMB 46,150,000. If the profit distribution plan is approved by the Shareholders by way of an ordinary resolution at the AGM to be held on 9 June 2017, the final dividend is expected to be distributed on 21 August 2017 to all Shareholders whose names appear on the register of the Company on 22 June 2017.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Audited Consolidated Cash Flow Results for the Year Ended December 31, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported audited consolidated cash flow results for the year ended December 31, 2016. For the year, the company reported net cash generated from operating activities of RMB 140.6 million compared to RMB 96.3 million, purchase of property, plant and equipment of RMB 46.3 million compared to RMB 38.3 million and purchase of intangible assets of RMB 0.5 million compared to RMB 1.5 million for the last year.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported audited consolidated earnings results for the year ended December 31, 2016. For the year, the company’s revenue was RMB 621,870,000 against RMB 579,463,000 a year ago. Operating profit was RMB 155,117,000 against RMB 153,056,000 a year ago. Profit before income tax was RMB 150,838,000 against RMB 145,950,000 a year ago. Profit for the year attributable to shareholders of the company was RMB 138,708,000 or RMB 0.1503 basic and diluted per share against RMB 127,723,000 or RMB 0.1384 basic and diluted per share a year ago. EBITDA was RMB 185,970,000 against RMB 182,070,000 a year ago. The total revenue for the year 2016 mainly came from the sale of medical products. The main source of total revenue for the year 2016 was nearly the same as that for the year of 2015.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1349 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1349.
View Industry Companies
 

Industry Analysis

1349

Industry Average

Valuation 1349 Industry Range
Price/Earnings 35.2x
Price/Sales 7.8x
Price/Book 5.8x
Price/Cash Flow 35.2x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHANGHAI FUDAN-ZHANGJIANG-H, please visit www.fd-zj.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.